Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Toxicity studies with flutrimazole.

M L Vericat1, J García Rafanell, J Forn

  • 1Research Center, J. Uriach & Cía, S.A., Barcelona, Spain.

Arzneimittel-Forschung
|June 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XY disorder of sex development.

The Journal of clinical endocrinology and metabolism·2010
Same author

Radio imaging of the very-high-energy gamma-ray emission region in the central engine of a radio galaxy.

Science (New York, N.Y.)·2009
Same author

Observation of pulsed gamma-rays above 25 GeV from the Crab pulsar with MAGIC.

Science (New York, N.Y.)·2008
Same author

Very-high-energy gamma rays from a distant quasar: how transparent is the universe?

Science (New York, N.Y.)·2008
Same author

Variable very-high-energy gamma-ray emission from the microquasar LS I +61 303.

Science (New York, N.Y.)·2006
Same author

Effect of chronic lithium treatment on the turnover of alpha2-adrenoceptors after chemical inactivation in rats.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2004

Flutrimazole (CAS 119006-77-8) cream demonstrates very low acute toxicity and excellent dermal tolerance. It is non-irritating, non-sensitizing, and lacks phototoxic or photoallergic potential, supporting safe topical use.

Area of Science:

  • Dermatology
  • Pharmacology
  • Toxicology

Background:

  • Flutrimazole (CAS 119006-77-8) is a novel imidazole antifungal agent developed for topical application.
  • Assessing the safety profile of new topical agents is crucial before widespread clinical use.

Purpose of the Study:

  • To evaluate the toxicological profile of flutrimazole, focusing on acute toxicity, irritation, dermal tolerance, and sensitization potential.
  • To compare the dermal tolerance of flutrimazole cream with a clotrimazole-based formulation.

Main Methods:

  • Acute toxicity studies (LD50) in mice and rats via oral and intraperitoneal routes.
  • Acute ocular and dermal irritation tests in rabbits.
  • Repeated dose (21-day) dermal tolerance studies in rabbits.
  • Sensitization, phototoxicity, and photoallergic potential assessments in guinea pigs.

Related Experiment Videos

  • Histopathological examinations to corroborate irritation and tolerance findings.

    • Main Results:

    • Flutrimazole exhibited very low acute toxicity with LD50 values >= 1000 mg/kg in rodents.
    • No significant ocular or dermal irritation was observed with 1% flutrimazole cream compared to its excipient.
    • Flutrimazole cream demonstrated superior dermal tolerance over a commercial clotrimazole cream (irritation index 1.2 vs. 3.7, p<0.01).
    • The agent was found to be non-sensitizing, non-phototoxic, and non-photoallergic in guinea pig models.
    • Minimal systemic absorption of flutrimazole from the topical formulation was noted.

    Conclusions:

    • Flutrimazole cream possesses a favorable safety profile, characterized by low systemic toxicity and excellent local tolerance.
    • The findings support the safe use of 1% flutrimazole cream for topical applications without significant concerns regarding systemic toxicity or dermal adverse effects.